RBSH (Rebus Hldgs) Debt-to-Equity: -0.06 (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rebus Hldgs Debt-to-Equity?

Rebus Hldgs RBSH -99.00% Debt-to-Equity is -0.06 as of Jun. 2023.

Rebus Hldgs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.31 Mil. Rebus Hldgs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.00 Mil. Rebus Hldgs's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-5.61 Mil. Rebus Hldgs's debt to equity for the quarter that ended in Jun. 2023 was -0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Rebus Hldgs's Debt-to-Equity or its related term are showing as below:

RBSH's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Rebus Hldgs  (OTCPK:RBSH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Rebus Hldgs Debt-to-Equity Related Terms

Rebus Hldgs Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Rebus Hldgs's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rebus Hldgs Debt-to-Equity Chart

Rebus Hldgs Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.32 -0.32 -0.15 -0.10 -0.06

Rebus Hldgs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.05 -0.06 -0.06 -0.06

RBSH vs KRBP, CNBX, EVFM: Debt-to-Equity Comparison

For the Biotechnology subindustry, Rebus Hldgs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rebus Hldgs Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rebus Hldgs's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Rebus Hldgs's Debt-to-Equity falls into.


Rebus Hldgs Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Rebus Hldgs's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.31 + 0) / -5.237
=-0.06

Rebus Hldgs's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.31 + 0) / -5.61
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.06 mean?
Rebus Hldgs (RBSH) has a Debt-to-Equity of -0.06 as of Jun. 2023. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rebus Hldgs and its competitors.
Is Rebus Hldgs' Debt-to-Equity too high?
Rebus Hldgs' current Debt-to-Equity is -0.06.
How does Rebus Hldgs' Debt-to-Equity compare to KRBP and CNBX?
Rebus Hldgs' Debt-to-Equity of -0.06 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rebus Hldgs and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rebus Hldgs's current Debt-to-Equity is -0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rebus Hldgs stock overvalued right now?
Rebus Hldgs (RBSH) has a current Debt-to-Equity of -0.06. The current Debt-to-Equity is -0.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Rebus Hldgs (RBSH), the current Debt-to-Equity is -0.06 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rebus Hldgs Business Description

Address 2629 Townsgate Road, Suite 215, Westlake Village, CA, USA, 91361
Rebus Hldgs Inc is an early-stage, pre-revenue, pharmaceutical company that is focused on the development of prodrug cancer therapeutics for the treatment of disease. The company along with its subsidiaries is engaged in the production of small-molecule adenosine receptor modulators. Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation.